A detailed history of Victory Capital Management Inc transactions in Nektar Therapeutics stock. As of the latest transaction made, Victory Capital Management Inc holds 22,567 shares of NKTR stock, worth $20,987. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,567
Previous 23,031 2.01%
Holding current value
$20,987
Previous $28,000 3.57%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$1.11 - $1.48 $515 - $686
-464 Reduced 2.01%
22,567 $29,000
Q2 2024

Aug 05, 2024

BUY
$0.9 - $1.83 $20,727 - $42,146
23,031 New
23,031 $28,000
Q3 2023

Nov 06, 2023

BUY
$0.51 - $1.05 $261 - $537
512 Added 2.56%
20,475 $12,000
Q2 2023

Jul 27, 2023

SELL
$0.53 - $1.03 $6,433 - $12,502
-12,138 Reduced 37.81%
19,963 $11,000
Q1 2023

May 02, 2023

SELL
$0.64 - $3.15 $5,430 - $26,727
-8,485 Reduced 20.91%
32,101 $22,000
Q4 2022

Feb 09, 2023

SELL
$2.03 - $4.28 $18 - $38
-9 Reduced 0.02%
40,586 $91,000
Q3 2022

Nov 02, 2022

BUY
$3.04 - $5.14 $16,455 - $27,822
5,413 Added 15.39%
40,595 $130,000
Q2 2022

Aug 01, 2022

BUY
$3.17 - $6.17 $4,098 - $7,977
1,293 Added 3.82%
35,182 $134,000
Q1 2022

May 04, 2022

BUY
$4.16 - $13.72 $78,432 - $258,676
18,854 Added 125.4%
33,889 $140,000
Q4 2021

Feb 07, 2022

SELL
$10.83 - $18.41 $1,397 - $2,374
-129 Reduced 0.85%
15,035 $203,000
Q3 2021

Nov 02, 2021

SELL
$13.07 - $18.84 $797 - $1,149
-61 Reduced 0.4%
15,164 $272,000
Q2 2021

Aug 03, 2021

SELL
$16.52 - $20.4 $2,725 - $3,365
-165 Reduced 1.07%
15,225 $261,000
Q1 2021

May 04, 2021

BUY
$16.56 - $25.46 $1,043 - $1,603
63 Added 0.41%
15,390 $308,000
Q4 2020

Feb 01, 2021

BUY
$15.77 - $19.03 $12,978 - $15,661
823 Added 5.67%
15,327 $261,000
Q3 2020

Nov 09, 2020

SELL
$16.59 - $24.79 $7,614 - $11,378
-459 Reduced 3.07%
14,504 $241,000
Q2 2020

Aug 07, 2020

SELL
$16.86 - $23.44 $531,494 - $738,922
-31,524 Reduced 67.81%
14,963 $347,000
Q1 2020

May 04, 2020

BUY
$14.47 - $27.96 $349,276 - $674,898
24,138 Added 108.0%
46,487 $830,000
Q4 2019

Feb 06, 2020

SELL
$15.87 - $23.12 $408,747 - $595,478
-25,756 Reduced 53.54%
22,349 $482,000
Q4 2019

Feb 04, 2020

BUY
$15.87 - $23.12 $728,623 - $1.06 Million
45,912 Added 2093.57%
48,105 $957,000
Q3 2019

Nov 12, 2019

SELL
$16.91 - $36.27 $5,157 - $11,062
-305 Reduced 12.21%
2,193 $40,000
Q2 2019

Aug 15, 2019

SELL
$31.0 - $36.3 $1,643 - $1,923
-53 Reduced 2.08%
2,498 $89,000
Q1 2019

May 03, 2019

BUY
$31.58 - $46.35 $252 - $370
8 Added 0.31%
2,551 $86,000
Q4 2018

Feb 05, 2019

SELL
$30.43 - $56.65 $517 - $963
-17 Reduced 0.66%
2,543 $84,000
Q3 2018

Nov 01, 2018

SELL
$46.46 - $68.49 $18,072 - $26,642
-389 Reduced 13.19%
2,560 $156,000
Q2 2018

Aug 02, 2018

SELL
$46.25 - $104.45 $24,281 - $54,836
-525 Reduced 15.11%
2,949 $144,000
Q1 2018

May 04, 2018

BUY
$57.4 - $108.44 $117,497 - $221,976
2,047 Added 143.45%
3,474 $369,000
Q4 2017

Feb 01, 2018

SELL
$23.02 - $60.5 $45,579 - $119,790
-1,980 Reduced 58.12%
1,427 $85,000
Q2 2017

Aug 07, 2017

BUY
N/A
3,407
3,407 $67,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $174M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.